Treatment of psoriasis with different dosage regimens of etanercept: Preliminary results from the Taranta Plastic Study Group

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 3, 2010, Pages 797-802

  Cassano, N ^a   Loconsole, F ^a   Miracapillo, A ^b   Travaglini, M ^c   Digiuseppe, M D ^d   Congedo, M ^e   Galluccio, A ^f   Buquicchio, R ^a   Mastrandrea, V ^a   Filieri, M ^c   Raho, G ^e   Pezza, M ^f   Vena, Gino A ^a  

^a UNIVERSITY OF BARI   (Italy)

^b MIULLI GENERAL HOSPITAL   (Italy)

^c Ospedale Perrino   (Italy)

^d Ospedale SS Annunziata   (Italy)

^e VITO FAZZI HOSPITAL   (Italy)

^f Unit of Dermatology   (Italy)

Author keywords

Dosage; Etanercept treatment; PASI 50 response; Psoriasis

Indexed keywords

ETANERCEPT;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; RECURRENT DISEASE; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 78149277496     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300314     Document Type: Article

References (20)

1. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, D'Auria L, Fazio M, Ameglio F. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11:115-8.
2. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175:2721-9.
3. Tan JK, Aphale A, Malavita R, Sun Y, Gottlieb AB. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc 2007; 12:38-45.
4. Cordiali-Fei P, Ardigò M, Mastroianni A, Giuliani A, D' Agosto G, Bordignon V, Trento E, Vento A, Berardesca E. Serum cytokines and bioumoral immunological characterization of psoriatic patients in long term etanercept treatment. Int J Immunopathol Pharmacol 2008; 21:643-9.
5. Campanati A, Goteri G, Simonetti O, et al. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol 2009; 22:371-7.
6. Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 2007; 12:9-15.
7. Altomare G, Ayala F, Berardesca E, et al. Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatol Ther 2008; 21(S):1-14.
8. Castelo-Soccio L, Van Voorhees AS. Long-term efficacy of biologics in dermatology. Dermatol Ther 2009; 22:22-33.
9. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther 2009; 22:431-40.
10. Leonardi C, Powers J, Matheson R, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept Psoriasis Study Group. Etanercept monotherapy in psoriasis. N Engl J Med 2003; 349:2014-22.
11. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L. Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304-12.
12. Summary of Product Characteristics* - 16/07/2009 Enbrel-H-C-262-II-108.
13. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
14. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133:1433-40.
15. Abeni D, Picardi A, Puddu P, Pasquini P, Chren MM. Construction and validation of the Italian version of Skindex-29, a new instrument to measure quality of life in dermatology. G Ital Dermatol Venereol 2001; 136:73-6.
16. Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM. Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology 2002; 204:43-9.
17. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56:598-603.
18. Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, Freundlich B, Stevens SR. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008; 11:400-7.
19. Daudén E, Griffiths C, Ortonne JP, Kragballe K, Molta C, Robertson D, Pedersen R, Estojak J, Boggs R. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23:1374-82.
20. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Ormerod AD. Br J Dermatol 2009; 161:987-1019.